{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:15:10Z","timestamp":1789593310783,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s10637-014-0141-2","type":"journal-article","created":{"date-parts":[[2014,7,31]],"date-time":"2014-07-31T04:27:56Z","timestamp":1406780876000},"page":"1096-1104","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells"],"prefix":"10.1007","volume":"32","author":[{"given":"Nicole","family":"Grabinski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Ewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,1]]},"reference":[{"issue":"6","key":"141_CR1","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","volume":"49","author":"J Ferlay","year":"2013","unstructured":"Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6):1374\u20131403. doi:10.1016\/j.ejca.2012.12.027","journal-title":"Eur J Cancer"},{"issue":"4785","key":"141_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235(4785):177\u2013182","journal-title":"Science"},{"issue":"3","key":"141_CR3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/path.1370","volume":"200","author":"CJ Witton","year":"2003","unstructured":"Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM (2003) Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 200(3):290\u2013297. doi:10.1002\/path.1370","journal-title":"J Pathol"},{"issue":"3","key":"141_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ccr.2014.02.025","volume":"25","author":"CL Arteaga","year":"2014","unstructured":"Arteaga CL, Engelman JA (2014) ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 25(3):282\u2013303. doi:10.1016\/j.ccr.2014.02.025","journal-title":"Cancer Cell"},{"issue":"4730","key":"141_CR5","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1126\/science.2999974","volume":"230","author":"L Coussens","year":"1985","unstructured":"Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U et al (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230(4730):1132\u20131139","journal-title":"Science"},{"issue":"2","key":"141_CR6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1210\/er.2006-0045","volume":"29","author":"G Arpino","year":"2008","unstructured":"Arpino G, Wiechmann L, Osborne CK, Schiff R (2008) Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29(2):217\u2013233. doi:10.1210\/er.2006-0045","journal-title":"Endocr Rev"},{"key":"141_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-014-0967-3","author":"H Modjtahedi","year":"2014","unstructured":"Modjtahedi H, Cho BC, Michel MC, Solca F (2014) A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn Schmiedeberg\u2019s Arch Pharmacol. doi:10.1007\/s00210-014-0967-3","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"issue":"1","key":"141_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1615\/CritRevOncog.v17.i1.20","volume":"17","author":"BN Rexer","year":"2012","unstructured":"Rexer BN, Arteaga CL (2012) Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog 17(1):1\u201316","journal-title":"Crit Rev Oncog"},{"issue":"7276","key":"141_CR9","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/nature08622","volume":"462","author":"W Zhou","year":"2009","unstructured":"Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, Cortot AB, Chirieac L, Iacob RE, Padera R, Engen JR, Wong KK, Eck MJ, Gray NS, Janne PA (2009) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462(7276):1070\u20131074. doi:10.1038\/nature08622","journal-title":"Nature"},{"key":"141_CR10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1146\/annurev.pharmtox.45.120403.100124","volume":"45","author":"R Tibes","year":"2005","unstructured":"Tibes R, Trent J, Kurzrock R (2005) Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Annu Rev Pharmacol Toxicol 45:357\u2013384. doi:10.1146\/annurev.pharmtox.45.120403.100124","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"12","key":"141_CR11","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-13-0314","volume":"3","author":"AO Walter","year":"2013","unstructured":"Walter AO, Sjin RT, Haringsma HJ, Ohashi K, Sun J, Lee K, Dubrovskiy A, Labenski M, Zhu Z, Wang Z, Sheets M, St Martin T, Karp R, van Kalken D, Chaturvedi P, Niu D, Nacht M, Petter RC, Westlin W, Lin K, Jaw-Tsai S, Raponi M, Van Dyke T, Etter J, Weaver Z, Pao W, Singh J, Simmons AD, Harding TC, Allen A (2013) Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov 3(12):1404\u20131415. doi:10.1158\/2159-8290.CD-13-0314","journal-title":"Cancer Discov"},{"issue":"37","key":"141_CR12","doi-asserted-by":"publisher","first-page":"15046","DOI":"10.1073\/pnas.1111239108","volume":"108","author":"AL Garske","year":"2011","unstructured":"Garske AL, Peters U, Cortesi AT, Perez JL, Shokat KM (2011) Chemical genetic strategy for targeting protein kinases based on covalent complementarity. Proc Natl Acad Sci U S A 108(37):15046\u201315052. doi:10.1073\/pnas.1111239108","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"141_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/nchembio866","volume":"3","author":"JA Blair","year":"2007","unstructured":"Blair JA, Rauh D, Kung C, Yun CH, Fan QW, Rode H, Zhang C, Eck MJ, Weiss WA, Shokat KM (2007) Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol 3(4):229\u2013238. doi:10.1038\/nchembio866","journal-title":"Nat Chem Biol"},{"issue":"5726","key":"141_CR14","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science1108367","volume":"308","author":"MS Cohen","year":"2005","unstructured":"Cohen MS, Zhang C, Shokat KM, Taunton J (2005) Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 308(5726):1318\u20131321. doi:10.1126\/science1108367","journal-title":"Science"},{"issue":"1","key":"141_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nrc2559","volume":"9","author":"J Zhang","year":"2009","unstructured":"Zhang J, Yang PL, Gray NS (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9(1):28\u201339. doi:10.1038\/nrc2559","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"141_CR16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1189\/jlb.0513307","volume":"95","author":"G Lopez-Herrera","year":"2014","unstructured":"Lopez-Herrera G, Vargas-Hernandez A, Gonzalez-Serrano ME, Berron-Ruiz L, Rodriguez-Alba JC, Espinosa-Rosales F, Santos-Argumedo L (2014) Bruton\u2019s tyrosine kinase\u2014an integral protein of B cell development that also has an essential role in the innate immune system. J Leukoc Biol 95(2):243\u2013250. doi:10.1189\/jlb.0513307","journal-title":"J Leukoc Biol"},{"issue":"4","key":"141_CR17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrc3702","volume":"14","author":"RW Hendriks","year":"2014","unstructured":"Hendriks RW, Yuvaraj S, Kil LP (2014) Targeting Bruton\u2019s tyrosine kinase in B cell malignancies. Nat Rev Cancer 14(4):219\u2013232. doi:10.1038\/nrc3702","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"141_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3109\/08830185.2012.664797","volume":"31","author":"JJ Buggy","year":"2012","unstructured":"Buggy JJ, Elias L (2012) Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol 31(2):119\u2013132. doi:10.3109\/08830185.2012.664797","journal-title":"Int Rev Immunol"},{"issue":"5","key":"141_CR19","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1021\/jm101396q","volume":"54","author":"E Leproult","year":"2011","unstructured":"Leproult E, Barluenga S, Moras D, Wurtz JM, Winssinger N (2011) Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors. J Med Chem 54(5):1347\u20131355. doi:10.1021\/jm101396q","journal-title":"J Med Chem"},{"issue":"1","key":"141_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11899-012-0147-9","volume":"8","author":"JR Brown","year":"2013","unstructured":"Brown JR (2013) Ibrutinib (PCI-32765), the first BTK (Bruton\u2019s tyrosine kinase) inhibitor in clinical trials. Curr Hematol Malignancy Rep 8(1):1\u20136. doi:10.1007\/s11899-012-0147-9","journal-title":"Curr Hematol Malignancy Rep"},{"issue":"4","key":"141_CR21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2174\/1871525712666140115143914","volume":"11","author":"AL Dias","year":"2014","unstructured":"Dias AL, Jain D (2014) Ibrutinib: a New frontier in the treatment of chronic lymphocytic leukemia by Bruton\u2019s tyrosine kinase inhibition. Cardiovasc Hematol Agents Med Chem 11(4):265\u2013271","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"issue":"5","key":"141_CR22","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.cellsig.2014.01.018","volume":"26","author":"N Grabinski","year":"2014","unstructured":"Grabinski N, Mollmann K, Milde-Langosch K, Muller V, Schumacher U, Brandt B, Pantel K, Jucker M (2014) AKT3 regulates ErbB2, ErbB3 and estrogen receptor alpha expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice. Cell Signal 26(5):1021\u20131029. doi:10.1016\/j.cellsig.2014.01.018","journal-title":"Cell Signal"},{"key":"141_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27\u201355","journal-title":"Adv Enzyme Regul"},{"key":"141_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1476-4598-11-85","volume":"11","author":"N Grabinski","year":"2012","unstructured":"Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B, Jucker M (2012) Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer 11:85. doi:10.1186\/1476-4598-11-85","journal-title":"Mol Cancer"},{"issue":"15","key":"141_CR25","doi-asserted-by":"publisher","first-page":"8933","DOI":"10.1073\/pnas.1537685100","volume":"100","author":"T Holbro","year":"2003","unstructured":"Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF 3rd, Hynes NE (2003) The ErbB2\/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 100(15):8933\u20138938. doi:10.1073\/pnas.1537685100","journal-title":"Proc Natl Acad Sci U S A"},{"key":"141_CR26","doi-asserted-by":"publisher","DOI":"10.1021\/cb4008524","author":"H Wu","year":"2014","unstructured":"Wu H, Wang W, Liu F, Weisberg EL, Tian B, Chen Y, Li B, Wang A, Wang B, Zhao Z, McMillin DW, Hu C, Li H, Wang J, Liang Y, Buhrlage SJ, Liang J, Liu J, Yang G, Brown JR, Treon SP, Mitsiades CS, Griffin JD, Liu Q, Gray NS (2014) Discovery of a potent covalent BTK inhibitor for B-cell lymphoma. ACS Chem Biol. doi:10.1021\/cb4008524","journal-title":"ACS Chem Biol"},{"issue":"45","key":"141_CR27","doi-asserted-by":"publisher","first-page":"32689","DOI":"10.1074\/jbc.M703412200","volume":"282","author":"X Jiang","year":"2007","unstructured":"Jiang X, Borgesi RA, McKnight NC, Kaur R, Carpenter CL, Balk SP (2007) Activation of nonreceptor tyrosine kinase Bmx\/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells. J Biol Chem 282(45):32689\u201332698. doi:10.1074\/jbc.M703412200","journal-title":"J Biol Chem"},{"issue":"277","key":"141_CR28","doi-asserted-by":"publisher","first-page":"ra40","DOI":"10.1126\/scisignal.2003936","volume":"6","author":"S Chen","year":"2013","unstructured":"Chen S, Jiang X, Gewinner CA, Asara JM, Simon NI, Cai C, Cantley LC, Balk SP (2013) Tyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinases. Sci Signal 6(277):ra40. doi:10.1126\/scisignal.2003936","journal-title":"Sci Signal"},{"issue":"11","key":"141_CR29","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.bcp.2012.07.031","volume":"84","author":"C Carmi","year":"2012","unstructured":"Carmi C, Mor M, Petronini PG, Alfieri RR (2012) Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. Biochem Pharmacol 84(11):1388\u20131399. doi:10.1016\/j.bcp.2012.07.031","journal-title":"Biochem Pharmacol"},{"issue":"22","key":"141_CR30","doi-asserted-by":"publisher","first-page":"5916","DOI":"10.1016\/j.bmcl.2008.07.062","volume":"18","author":"W Hur","year":"2008","unstructured":"Hur W, Velentza A, Kim S, Flatauer L, Jiang X, Valente D, Mason DE, Suzuki M, Larson B, Zhang J, Zagorska A, Didonato M, Nagle A, Warmuth M, Balk SP, Peters EC, Gray NS (2008) Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase. Bioorg Med Chem Lett 18(22):5916\u20135919. doi:10.1016\/j.bmcl.2008.07.062","journal-title":"Bioorg Med Chem Lett"},{"issue":"6","key":"141_CR31","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1073\/pnas.1311846111","volume":"111","author":"LA Mathews Griner","year":"2014","unstructured":"Mathews Griner LA, Guha R, Shinn P, Young RM, Keller JM, Liu D, Goldlust IS, Yasgar A, McKnight C, Boxer MB, Duveau DY, Jiang JK, Michael S, Mierzwa T, Huang W, Walsh MJ, Mott BT, Patel P, Leister W, Maloney DJ, Leclair CA, Rai G, Jadhav A, Peyser BD, Austin CP, Martin SE, Simeonov A, Ferrer M, Staudt LM, Thomas CJ (2014) High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A 111(6):2349\u20132354. doi:10.1073\/pnas.1311846111","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0141-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-014-0141-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0141-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0141-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:56:14Z","timestamp":1678510574000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-014-0141-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,1]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["141"],"URL":"https:\/\/doi.org\/10.1007\/s10637-014-0141-2","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,1]]},"assertion":[{"value":"6 June 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}